HRP20170349T1 - Novi derivati pirola, postupak njihove priprave i farmaceutski pripravci koji ih sadrže - Google Patents
Novi derivati pirola, postupak njihove priprave i farmaceutski pripravci koji ih sadrže Download PDFInfo
- Publication number
- HRP20170349T1 HRP20170349T1 HRP20170349TT HRP20170349T HRP20170349T1 HR P20170349 T1 HRP20170349 T1 HR P20170349T1 HR P20170349T T HRP20170349T T HR P20170349TT HR P20170349 T HRP20170349 T HR P20170349T HR P20170349 T1 HRP20170349 T1 HR P20170349T1
- Authority
- HR
- Croatia
- Prior art keywords
- formula
- compound
- dimethyl
- pyrrole
- hydroxyphenyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 4
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000003233 pyrroles Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 40
- -1 3-fluoro-4-hydroxyphenyl group Chemical group 0.000 claims 13
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 12
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 11
- 239000002253 acid Substances 0.000 claims 10
- 239000000825 pharmaceutical preparation Substances 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 7
- 125000005843 halogen group Chemical group 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 239000003513 alkali Substances 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 206010005003 Bladder cancer Diseases 0.000 claims 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 208000026310 Breast neoplasm Diseases 0.000 claims 4
- 206010009944 Colon cancer Diseases 0.000 claims 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 4
- 206010033128 Ovarian cancer Diseases 0.000 claims 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 4
- 206010060862 Prostate cancer Diseases 0.000 claims 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 4
- 206010041067 Small cell lung cancer Diseases 0.000 claims 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 4
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 4
- 239000002585 base Substances 0.000 claims 4
- 210000004556 brain Anatomy 0.000 claims 4
- 210000000481 breast Anatomy 0.000 claims 4
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 4
- 208000029742 colonic neoplasm Diseases 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 201000004101 esophageal cancer Diseases 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 201000007270 liver cancer Diseases 0.000 claims 4
- 208000014018 liver neoplasm Diseases 0.000 claims 4
- 208000003747 lymphoid leukemia Diseases 0.000 claims 4
- 230000003211 malignant effect Effects 0.000 claims 4
- 201000001441 melanoma Diseases 0.000 claims 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 4
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 4
- 210000003932 urinary bladder Anatomy 0.000 claims 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims 4
- 206010046766 uterine cancer Diseases 0.000 claims 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 3
- 201000000050 myeloid neoplasm Diseases 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 125000006685 (C1-C6) polyhaloalkyl group Chemical group 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 claims 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 230000008878 coupling Effects 0.000 claims 2
- 238000010168 coupling process Methods 0.000 claims 2
- 238000005859 coupling reaction Methods 0.000 claims 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 210000003238 esophagus Anatomy 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 2
- 210000000987 immune system Anatomy 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 238000000926 separation method Methods 0.000 claims 2
- 125000003003 spiro group Chemical group 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 239000011593 sulfur Chemical group 0.000 claims 2
- 238000003786 synthesis reaction Methods 0.000 claims 2
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 1
- 125000006091 1,3-dioxolane group Chemical group 0.000 claims 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical group C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 claims 1
- GVLRTOYGRNLSDW-UHFFFAOYSA-N 1h-pyrazolo[3,4-b]pyridine Chemical compound C1=CC=C2C=NNC2=N1 GVLRTOYGRNLSDW-UHFFFAOYSA-N 0.000 claims 1
- XWIYUCRMWCHYJR-UHFFFAOYSA-N 1h-pyrrolo[3,2-b]pyridine Chemical compound C1=CC=C2NC=CC2=N1 XWIYUCRMWCHYJR-UHFFFAOYSA-N 0.000 claims 1
- ZFFYPGZDXUPKNK-UHFFFAOYSA-N 2,3-dihydro-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CN=C2NCCC2=C1 ZFFYPGZDXUPKNK-UHFFFAOYSA-N 0.000 claims 1
- VEKIYFGCEAJDDT-UHFFFAOYSA-N 2-pyridin-3-ylpyridine Chemical compound N1=CC=CC=C1C1=CC=CN=C1 VEKIYFGCEAJDDT-UHFFFAOYSA-N 0.000 claims 1
- GRFNBEZIAWKNCO-UHFFFAOYSA-N 3-pyridinol Chemical group OC1=CC=CN=C1 GRFNBEZIAWKNCO-UHFFFAOYSA-N 0.000 claims 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- IMOMYGYJCIBYOD-JOCHJYFZSA-N 5-[5-chloro-2-[(3R)-3-methyl-3,4-dihydro-1H-isoquinoline-2-carbonyl]phenyl]-N-(4-hydroxyphenyl)-1,2-dimethyl-N-pyridin-4-ylpyrrole-3-carboxamide Chemical compound C[C@@H]1Cc2ccccc2CN1C(=O)c1ccc(Cl)cc1-c1cc(C(=O)N(c2ccncc2)c2ccc(O)cc2)c(C)n1C IMOMYGYJCIBYOD-JOCHJYFZSA-N 0.000 claims 1
- NUMXZEYOUGENSA-PMERELPUSA-N 5-[5-chloro-2-[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydro-1H-isoquinoline-2-carbonyl]phenyl]-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methylpyrazol-4-yl)pyrrole-3-carboxamide Chemical compound Cc1c(cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C)C(=O)N(c1cnn(C)c1)c1ccc(O)cc1 NUMXZEYOUGENSA-PMERELPUSA-N 0.000 claims 1
- SOMTYTOPJKWQJH-UMSFTDKQSA-N 5-[5-chloro-2-[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydro-1H-isoquinoline-2-carbonyl]phenyl]-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methylpyrrolo[2,3-b]pyridin-5-yl)pyrrole-3-carboxamide Chemical compound Cc1c(cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C)C(=O)N(c1ccc(O)cc1)c1cnc2n(C)ccc2c1 SOMTYTOPJKWQJH-UMSFTDKQSA-N 0.000 claims 1
- VNNWQLOUMFCVJD-XIFFEERXSA-N 5-[5-chloro-2-[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydro-1H-isoquinoline-2-carbonyl]phenyl]-N-(5-cyano-1,2-dimethylpyrrol-3-yl)-N-(4-hydroxyphenyl)-1,2-dimethylpyrrole-3-carboxamide Chemical compound Cc1c(cc(C#N)n1C)N(C(=O)c1cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n(C)c1C)c1ccc(O)cc1 VNNWQLOUMFCVJD-XIFFEERXSA-N 0.000 claims 1
- RIIZYGXLARDION-YTTGMZPUSA-N 5-[5-chloro-2-[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydro-1H-isoquinoline-2-carbonyl]phenyl]-N-(5-cyano-1-methylpyrrol-3-yl)-N-(4-hydroxyphenyl)-1,2-dimethylpyrrole-3-carboxamide Chemical compound Cc1c(cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C)C(=O)N(c1cc(C#N)n(C)c1)c1ccc(O)cc1 RIIZYGXLARDION-YTTGMZPUSA-N 0.000 claims 1
- XJAHZBYUSLAMHD-PMERELPUSA-N 5-[5-fluoro-2-[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydro-1H-isoquinoline-2-carbonyl]phenyl]-N-(4-hydroxyphenyl)-1,2-dimethyl-N-(1-methylpyrazol-4-yl)pyrrole-3-carboxamide Chemical compound Cc1c(cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C)C(=O)N(c1cnn(C)c1)c1ccc(O)cc1 XJAHZBYUSLAMHD-PMERELPUSA-N 0.000 claims 1
- KDOPAZIWBAHVJB-UHFFFAOYSA-N 5h-pyrrolo[3,2-d]pyrimidine Chemical compound C1=NC=C2NC=CC2=N1 KDOPAZIWBAHVJB-UHFFFAOYSA-N 0.000 claims 1
- NIBIFDYRZZMQPY-YTTGMZPUSA-N Cc1c(cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C)C(=O)N(c1ccncc1)c1ccc(O)cc1 Chemical compound Cc1c(cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C)C(=O)N(c1ccncc1)c1ccc(O)cc1 NIBIFDYRZZMQPY-YTTGMZPUSA-N 0.000 claims 1
- 238000007341 Heck reaction Methods 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- SGJLRGCZCVJUBB-JOCHJYFZSA-N N-(4-hydroxyphenyl)-1,2-dimethyl-5-[6-[(3R)-3-methyl-3,4-dihydro-1H-isoquinoline-2-carbonyl]-1,3-benzodioxol-5-yl]-N-pyridin-4-ylpyrrole-3-carboxamide Chemical compound C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2OCOc2cc1-c1cc(C(=O)N(c2ccncc2)c2ccc(O)cc2)c(C)n1C SGJLRGCZCVJUBB-JOCHJYFZSA-N 0.000 claims 1
- DYOFNMBIRDQGPE-XIFFEERXSA-N N-(5-cyano-1,2-dimethylpyrrol-3-yl)-5-[5-fluoro-2-[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydro-1H-isoquinoline-2-carbonyl]phenyl]-N-(4-hydroxyphenyl)-1,2-dimethylpyrrole-3-carboxamide Chemical compound Cc1c(cc(C#N)n1C)N(C(=O)c1cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n(C)c1C)c1ccc(O)cc1 DYOFNMBIRDQGPE-XIFFEERXSA-N 0.000 claims 1
- HVKNUMGVTAFZRT-YTTGMZPUSA-N N-(5-cyano-1-methylpyrrol-3-yl)-5-[5-fluoro-2-[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydro-1H-isoquinoline-2-carbonyl]phenyl]-N-(4-hydroxyphenyl)-1,2-dimethylpyrrole-3-carboxamide Chemical compound Cc1c(cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C)C(=O)N(c1cc(C#N)n(C)c1)c1ccc(O)cc1 HVKNUMGVTAFZRT-YTTGMZPUSA-N 0.000 claims 1
- 150000001204 N-oxides Chemical class 0.000 claims 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims 1
- 229940079156 Proteasome inhibitor Drugs 0.000 claims 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 1
- 150000001263 acyl chlorides Chemical class 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims 1
- 150000008064 anhydrides Chemical class 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000001640 apoptogenic effect Effects 0.000 claims 1
- 125000005110 aryl thio group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 235000010290 biphenyl Nutrition 0.000 claims 1
- 239000004305 biphenyl Substances 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 150000007942 carboxylates Chemical class 0.000 claims 1
- 239000003054 catalyst Substances 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 238000010511 deprotection reaction Methods 0.000 claims 1
- 125000004185 ester group Chemical group 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 1
- 231100000024 genotoxic Toxicity 0.000 claims 1
- 230000001738 genotoxic effect Effects 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 claims 1
- 239000000543 intermediate Substances 0.000 claims 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 230000000394 mitotic effect Effects 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 claims 1
- 229910052763 palladium Inorganic materials 0.000 claims 1
- 238000005897 peptide coupling reaction Methods 0.000 claims 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 239000002574 poison Substances 0.000 claims 1
- 231100000614 poison Toxicity 0.000 claims 1
- 125000006684 polyhaloalkyl group Polymers 0.000 claims 1
- 230000000861 pro-apoptotic effect Effects 0.000 claims 1
- 239000003207 proteasome inhibitor Substances 0.000 claims 1
- LDIJKUBTLZTFRG-UHFFFAOYSA-N pyrazolo[1,5-a]pyrimidine Chemical compound N1=CC=CN2N=CC=C21 LDIJKUBTLZTFRG-UHFFFAOYSA-N 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical group OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 239000007858 starting material Substances 0.000 claims 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 1
- 229930192474 thiophene Natural products 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
Claims (35)
1. Spoj formule (I):
[image]
naznačen time, da:
♦ A1 predstavlja atom vodika ili halogena, ravnu ili razgrananu (C1-C6)polihaloalkilnu skupinu, ravnu ili razgrananu (C1-C6)alkilnu skupinu ili cikloalkilnu skupinu,
♦ A2 predstavlja ravnu ili razgrananu (C1-C6)alkilnu skupinu po izboru supstituiranu sa skupinom odabranom od halogena, hidroksi, ravnog ili razgrananog (C1-C6)alkoksi, NR'R" i morfolina ili A2 predstavlja ravnu ili razgrananu (C1-C6)polihaloalkilnu skupinu ili ciklopropilnu skupinu, gdje se podrazumijeva da R' i R", svaki neovisno jedan o drugome, predstavljanju atom vodika ili ravnu ili razgrananu (C1-C6)alkilnu skupinu,
♦ T predstavlja atom vodika, ravnu ili razgrananu (C1-C6)alkilnu skupinu po izboru supstituiranu s jednim do tri atoma halogena, skupinu (C1-C4)alkil-NR1R2 ili skupinu (C1-C4)alkil-OR6,
♦ R1 i R2, svaki neovisno jedan o drugome, predstavljaju atom vodika ili ravnu ili razgrananu (C1-C6)alkilnu skupinu ili R1 i R2 tvore s dušikovim atomom koji ih nosi heterocikloalkil,
♦ R3 predstavlja arilnu ili heteroarilnu skupinu, pri čemu se podrazumijeva da jedan ili više ugljikovih atoma iz prethodnih skupina ili njihovi mogući supstituenti mogu biti deuterirani,
♦ R4 predstavlja fenilnu skupinu, 4-hidroksifenilnu skupinu, 3-fluoro-4-hidroksifenilnu skupinu, 2-hidroksipirimidinsku skupinu ili 3-hidroksipiridinsku skupinu, pri čemu se podrazumijeva da jedan ili više ugljikovih atoma iz prethodnih skupina ili njihovi mogući supstituenti mogu biti deuterirani,
♦ R5 predstavlja atom vodika ili atom halogena, ravnu ili razgrananu (C1-C6)alkilnu skupinu ili ravnu ili razgrananu (C1-C6)alkoksi skupinu,
♦ R6 predstavlja atom vodika ili ravnu ili razgrananu (C1-C6)alkilnu skupinu,
♦ Ra i Rd svaki predstavlja atom vodika i (Rb,Rc) zajedno s ugljikovim atomom koji ih nose tvore skupinu 1,3-dioksolana ili skupinu 1,4-dioksana ili Ra, Rc and Rd svaki predstavlja atom vodika i Rb predstavlja atom vodika ili halogena ili metoksi skupinu ili Ra i Rd svaki predstavlja atom vodika, Rb predstavlja atom vodika ili atom halogena i Rc predstavlja hidroski ili metoksi skupinu ili: Ra i Rd svaki predstavlja atom vodika, Rb predstavlja hidroksi ili metoksi skupinu i Rc predstavlja atom halogena, gdje se podrazumijeva kako:
- "aril" znači fenilna, naftilna, bifenilna ili indenilna skupina,
- "heteroaril" znači bilo koja mono- ili bi-ciklička skupina sastavljena od 5 do 10 članova prstena, koja ima najmanje jednu aromatsku polovicu i sastoji se od 1 do 4 heteroatoma odabrana od kisika, sumpora i dušika (uključujući kvaterne dušike),
- "cikloalkil" znači bilo koja mono- ili bi-ciklička, ne-aromatska, karbociklička skupina koja se sastoji od 3 do 10 članova prstena,
- "heterocikloalkil" znači bilo koja mono- ili bi-ciklička, ne-aromatska, kondenzirana ili spiro skupina koja se sastoji od 3 do 10 članova prstena i sadrži od 1 do 3 heteroatoma odabrana od kisika, sumpora, SO, SO2 i dušika, pri čemu je moguće za tako definirane arilne, heteroarilne, cikloalkilne i heterocikloalkilne skupine i skupine alkila, alkenil, alkinila i alkoksi da budu supstituirane s 1 do 3 skupine odabrane od ravnog ili razgrananog (C1-C6)alkila, (C3-C6)spiro, ravnog ili razgrananog (C1-C6)alkoksi, (C1-C6)alkil-S-, hidroksi, okso (ili N-oksida gdje je prikladno), nitro, cijano, -COOR', -OCOR', NR'R", ravnog ili razgrananog (C1-C6)polihaloalkila, trifluorometoksi, (C1-C6)alkilsulfonila, halogena, arila, heteroarila, ariloksi, ariltio, cikloalkila, heterocikloalkila po izboru supstituiranog s jednim ili više atoma halogena ili alkilnim skupinama,
njegove enantiomere i dijastereoizomere i njihove adicijske soli s s farmaceutski prihvatljivom kiselinom ili lužinom.
2. Spoj formule (1) u skladu s patentnim zahtjevom 1, naznačen time, da A1 predstavlja atom vodika ili metilnu skupinu.
3. Spoj formule (1) u skladu s patentnim zahtjevom 1 ili 2, naznačen time, da A1 i A2 oba predstavljaju metilnu skupinu.
4. Spoj formule (I) u skladu s jednim od patentnih zahtjeva 1 do 3, naznačen time, da T predstavlja metil, aminometil, (morfolin-4-il)metil, (4-metilpiperazin-l-il)metil, 2-(morfolin-4-il)etil, [2-(morfolin-4-il)etoksi]metil, hidroksimetil,[2-(dimetilamino)etoksi]metil, heksahidropirazino[2,l-c][l,4]oksazin-8(1H)-ilmetil, l-oksa-6-azaspiro[3.3]hept-6-ilmetil, 3-(morfolin-4-il)propilnu ili trifluorometilnu skupinu.
5. Spoj formule (1):
[image]
u skladu s patentnim zahtjevom 1, naznačen time, da
- A1, A2, Ra, Rb Rc Rd T, R4 i R5 jesu definirani u patentnim zahtjevima 1 do 4,
- R3 predstavlja skupinu odabranu od fenila, 1H-pirazola, 1H -indola, 1H -indazola, piridina, pirimidina, 1H -pirolo[ 2,3-bipiridina, 2,3-dihidro-1H -pirolo[2,3-b]piridina, 1H -benzimidazola, 1H -pirola, 1H -pirolo[2,3-cipiridina, 1H -pirolo[3,2-b]piridina, 5H-pirolo[3,2-d]pirimidina, tiofena, pirazina, 1H -pirazolo[3,4-b]piridina, 1,2-oksazola i pirazolo[1,5-a]pirimidina, te skupine po izboru imaju jednog ili više supstituenata odabrana od halogena, ravnog ili razgrananog (C1-C6)alkila, ravnog ili razgrananog (C1-C6)alkoksi, cijano, ciklopropila, oksetana, tetrahidrofurana, -CO-O-CH3, trideuteriometila, 2-(morfolin-4-il)etila i 2-(morfolin-4-il)etoksi, njihovih enantiomera i dijastereoizomera te njihovih adicijskih soli s farmaceutski prihvatljivom kiselinom ili lužinom.
6. Spoj formule (I) u skladu s patentnim zahtjevom 1, naznačen time, da je odabran iz sljedeće skupine:
-5-(5-kloro-2-{[(3S)-3-(morfolin-4-ilmetil)-3,4-dihidroizokinolin-2(1H)-il]-karbonil}fenil)-N-(4-hidroksifenil) -1.2-dimetil-N-(l-metil-1H-pirazol-4-il)-1H-pirol-3-karboksamid,
-5-(5-kloro-2-{[(3R)-3-metil-3,4-dihidroizokinolin-2(1H)-il]karbonil}fenil)-N-(4-hidroksifenil)-l,2-dimetil-N-(piridin-4-il)-1H-pirol-3-karboksamida,
-yV-(4-hidroksifenil)-l,2-dimetil-N-(l-metil-1H-pirazol-4-il)-5-(6-{[(3S)-3-(morfolin-4-iImetil)-3,4-dihidroizokinolin-2( 1 H)-il]karbonil}-1,3-benzoadioksol-5-il)-1 H-pirol-3-karboksamida,
- A'-(4-hidroksifenil)-l,2-dimetil-5-(6-{[(3R)-3-metil-3,4-dihidroizokinolin-2(1H)-il] karbonil}-1,3- benzodioksol -5-il)-N-(piridin-4-il)-l H-pirol-3-karboksamida,
- 5-(5-fluoro-2-{[(3S)-3-(morfolin-4-ilmetil)-3,4-dihidroizokinolin-2(1H)-il]-karbonil}fenil)-N-(4-hidroksifenil)-1,2-dimetil-N-( 1 -metil-1 H-pirazol-4-il)-1 H-pirol-3-karboksamida,
- 5-(5-kloro-2-{[(3S)-3-(morfolin-4-ilmetil)-3,4-dihidroizokinolin-2(1H)-il]-karbonil}fenil)-N-(4-hidroksifenil)-],2-dimetil-N-(l-metil-1H-pirolo[2,3-b]piridin-5-il)-1H-pirol-3-karboksamida,
-5-(5-kloro-2-{[(3S)-3-(morfolin-4-ilmetil)-3,4-dihidroizokinolin-2(1H)-il]-karbonil}fenil)-N-(4-hidroksifenil)-1,2-dimetil-N-(piridin-4-il)-1 H-pirol-3-karboksamida,
-5-(5-kloro-2-{[(3S)-3-(morfolin-4-ilmetil)-3,4-dihidroizokinolin-2(1H)-il]-karbonil}fenil)-N-(5-cijano-1-metil-1 H-pirol-3-il)-N-(4-hidroksifenil)-1,2-dimetil-1H-pirol-3-karboksamida,
-A'-(5-cijano-l-metil-1H-piroI-3-il)-5-(5-fluoro-2-{[(3S)-3-(morfolin-4-ilmetil)-3,4-dihidroizokinolin-2(1H)-il]karbonil}fenil)-N-(4-hidroksifenil)-1,2-dimetil-1H-pirol-3-karboksamida, -5-(5-kloro-2-{[(3S)-3-(morfolin-4-ilmetil)-3,4-dihidroizokinolin-2(1H)-il]-karbonil}fenil)-N-(5-cijano-l,2-dimetil-1H-pirol-3-il)-N-(4-hidroksifenil)-l,2-dimetil-1H-pirol-3-karboksamida,
-5-(5-kloro-2-{[(3S)-3-(morfolin-4-ilmetil)-3,4-dihidroizokinolin-2(1H)-il]-karbonil(fenil)-N-(4-hidroksifenil)-1,2-dimetil-N-( 1 -metil-2,3-dihidro-1H-pirolo[2,3-b]piridin-5-il)-1H-pirol-3-karboksamida,
-.V-(5-cijano-l,2-dimetil-1H-pirol-3-il)-5-(5-fluoro-2-{[(3S)-3-(morfolin-4-il-metil)-3,4dihidroizokinolin-2(1H)-ilJkarbonil(fenil)-N-(4-hidroksifenil)-l,2-dimetil-l H-pirol-3-karboksamida,
-5-(5-kloro-2-{[(3S)-3-(morfolin-4-ilmetil)-3,4-dihidroizokinolin-2(1H)-il]-karbonil}fenil)-N- [5-cijano-2-metil-l-(trideuteriometil)-1 H-pirol-3-il]-N-(4-hidroksifenil)-1,2-dimetil-1 H-pirol-3-karboksamida,
njihovih enantiomera i dijastereoizomera te njihovih adicijskih soli s farmaceutski prihvatljivom kiselinom ili lužinom.
7. Spoj formule (I) u skladu s patentnim zahtjevom 6, naznačen time, da je 5-(5-kloro-2-{[(3S)-3- (morfolin-4-ilmetil)-3,4-dihidroizokinolin-2(1H)-il]karbonil}fenil)-N-(4-hidroksifenil)-l,2-dimetil-N-(l-metil-1H-pirazol-4-il)-1H-pirol-3-karboksamid.
8. Spoj formule (1) u skladu s patentnim zahtjevom 6, naznačen time, da je 5-(5-kloro-2-{[(3R)-3-metil-3,4- dihidroizokinolin-2(1H)-il]karbonil}fenil)-N-(4-hidroksifenil)-l,2-dimetil-N-(piridin-4-il)-1H-pirol-3-karboksamid.
9. Spoj formule (I) u skladu s patentnim zahtjevom 6, naznačen time, da je N-(4-hidroksifenil)-1,2- dimetil-N-(1-metil-1H-pirazol-4-il)-5-(6-[(3S)-3-(morfolin-4-ilmetil)-3,4-dihidroizokinolin-2(1H)-il]karbonil}-1,3-benzodioksol-5-il)-1H-pirol-3-karboksamid.
10. Spoj formule (1) u skladu s patentnim zahtjevom 6, naznačen time, da je N-(4-hidroksifenil)-l,2- dimetil-5-(6-{[(3R)-3-metil-3,4-dihidroizokinolin-2(1H)-il]karbonil}-1,3-benzodioksol-5-il)-N-(piridin-4-il)-1H-pirol-3 karboksamid.
11. Spoj formule (1) u skladu s patentnim zahtjevom 6, naznačen time, da je 5-(5-fluoro-2-{[(3S)-3- (morfolin-4-ilmetil)-3,4-dihidroizokinolin-2(1H)-il]karbonil}fenil)-N-(4-hidroksifenil)-l,2-dimetil-N-(l-metil-1H-pirazol-4-il)-1H-pirol-3-karboksamid.
12. Spoj formule (1) u skladu s patentnim zahtjevom 6, naznačen time, da je 5-(5-kloro-2-{[(3S)-3- (morfolin-4-ilmetil)-3,4-dihidroizokinolin-2(1H)-il]karbonil}fenil)-N-(4-hidroksifenil)-1,2-dimetil-N-(1 -metil-1H-pirolo[2,3-b]piridin-5-il)-1H-pirol-3-karboksamid.
13. Spoj formule (1) u skladu s patentnim zahtjevom 6, naznačen time, da je 5-(5-kloro-2-{[(3S)-3- (morfolin-4-ilmetil)-3,4-dihidroizokinolin-2(1H)-il]karbonil}fenil)-N-(4-hidroksifenil)-1,2-dimetil-N-(piridin-4-il)-lH-pirol-3-karboksamid.
14. Spoj formule (I) u skladu s patentnim zahtjevom 6, naznačen time, da je 5-(5-kloro-2-{[(3S)-3- (morfolin-4-ilmetil)-3,4-dihidroizokinolin-2(1H)-il]karbonil}fenil)-N-(5-cijano-l-metil-1H-pirol-3-il)-N-(4-hidroksifenil)-l,2-dimetil-1H-pirol-3-karboksamid.
15. Spoj formule (I) u skladu s patentnim zahtjevom 6, naznačen time, da je N-(5-cijano-1- metil-1H-pirol-3-il)-5-(5-fluoro-2-{[(3S)-3-(morfolin-4-ilmetil)-3,4-dihidroizokinolin-2(1H)-il]karbonil}fenil)-N-(4-hidroksifenil)-1,2-dimetil-1H-pirol-3-karboksamid.
16. Spoj formule (I) u skladu s patentnim zahtjevom 6, naznačen time, da je 5-(5-kloro-2-{[(3S)-3- (morfolin-4-ilmetil)-3,4-dihidroizokinolin-2(1H)-il]karbonil}fenil)-N-(5-cijano-1,2-dimetil-1H-pirol-3-il)-N-(4-hidroksifenil)-1,2-dimetil-1H-pirol-3-karboksamid.
17. Spoj formule (I) u skladu s patentnim zahtjevom 6, naznačen time, da je 5-(5-kloro-2-{[(3S)-3- (morfolin-4-ilmetil)-3,4-dihidroizokinolin-2(1H)-il]karbonil}fenil)-N-(4-hidroksifenil)-l,2-dimetil-N-(l-metil-2,3-dihidro-1H-pirolo[2,3-b]piridin-5-il)-1H-pirol-3-karboksamid.
18. Spoj formule (I) u skladu s patentnim zahtjevom 6, naznačen time, da je N-(5-cijano-1,2-dimetil-1H- pirol-3-il)-5-(5-fluoro-2-{[(3S)-3-(morfolin-4-ilmetil)-3,4-dihidroizokinolin-2(1H)-il]karbonil}fenil)-N-(4-hidroksifenil)-1,2-dimetil-1H-pirol-3-karboksamid.
19. Spoj formule (I) u skladu s patentnim zahtjevom 6, naznačen time, da je 5-(5-kloro-2-{[(3S)-3- (morfolin-4-ilinctil)-3,4-dihidroizokinolin-2(1H)-il]karbonil}fenil)-N-[5-cijano-2-metil-l-(trideuteriometil)-1H-pirol-3-il]-N-(4-hidroksifenil)-l,2-dimetil-1H-pirol-3-karboksamid.
20. Postupak za pripravu spojeva formule (I) u skladu s patentnim zahtjevom I, naznačen time, da je kao početni materijal korišten spoj formule (II):
[image]
pri čemu su Ra, Rb, Rc i Rd kako je definirano za formulu (I),
koji spoj formule (II) je izložen Heckovoj reakciji u vodenom ili organskom mediju u nazočnosti paladijevog katalizatora, lužine, fosfina i spoja formule (III):
[image]
gdje su skupine A1 i A2 kako je definirano za formulu (I) i Alk predstavlja ravni ili razgranani (C1-C6)alkil, kako bi se dobio spoj formule (IV):
[image]
pri čemu su A1, A2, Ra, Rb. Rc i Rd definirani za formulu (I) i Alk je ranije gore definiran,
funkcija aldehida kojim je spoj formule (IV) oksidiran u karboksilnu kiselinu kako bi se dobio spoj formule (V):
[image]
pri čemu su A1; A2, Ra, Rb, Rc i Rd defininirani za formulu (I) i Alk je ranije gore definiran, koji se spoj formule (V) potom izlaže spajanju peptida sa spojem formule (VI):
[image]
pri čemu su T i R5 definirani za formulu (I), kako bi se dobio spoj formule (VII):
[image]
pri čemu su A1, A2, Ra, Rb, Rc i Rd, T i R5 definirano za formulu (I) i Alk je ranije gore definiran, esterska funkcija kojom je hidraliziran spoj formule (VII) kako bi se dobila odgovarajuća karboksilna kiselina ili karboksilat, koji se može pretvoriti u derivat kiseline poput primjerice u acil-klorida ili anhidrid prije spajanja s NHR3R4 aminom, gdje R3 i R4 imaju ista značenja kao za formulu (I), kako bi se dobio spoj formule (I), koji se spoj formule (I) može pročišćavati u skladu s uobičajenim tehnikama separacije, koji se može pretvoriti, ako je poželjno, u svoje adicijske soli s farmaceutski prihvatljivom kiselinom ili lužinom i koji je po izboru razdvojen u svoje izomere u skladu s uobičajenim tehnikama separacije, gdje se podrazumijeva, da se bilo koje vrijeme smatra prikladnim u smislu gore opisanog postupka, izvjesne skupine (hidroksi, amino...) reagensa ili intermedijera sinteze mogu biti zaštićene a potom im se skida zaštita u skladu sa zahtjevima sinteze.
21. Postupak u skladu s patentnim zahtjevom 20 za pripravu spoja formule (I) gdje je jedna od skupina R3 ili R4 supstituirana s hidroksi funkcijom, naznačen time, da je amin NHR3R4 prije toga izložen reakciji štiteći hidroksi funkciju prije bilo kakvog spajanja s karboksilnom kiselinom dobivenom od spoja formule (VII) ili s odgovarajućim derivatom kiseline, dobiveni zaštićeni spoj formule (I) naknadno se podvrgava reakciji skidanja zaštite a potom se po izboru pretvara u jednu od njegovih adicijskih soli s farmaceutski prihvatljivom kiselinom ili lužinom.
22. Farmaceutski pripravak koji sadrži spoj formule (1) u skladu s bilo kojim od patentnih zahtjeva 1 do 19 ili njegove adicijske soli s farmaceutski prihvatljivom kiselinom ili lužinom, naznačen time, daje u kombinaciji s jednim ili više farmaceutski prihvatljivih ekscipijensa.
23. Farmaceutski pripravak u skladu s patentnim zahtjevom 22, naznačen time, da je za uporabu kao pro-apoptotičko sredstvo.
24. Farmaceutski pripravak u skladu s patentnim zahtjevom 22, naznačen time, da je za uporabu u liječenju karcinoma, autoimunih bolesti i bolesti imunog sustava.
25. Farmaceutski pripravak u skladu s patentnim zahtjevom 22, naznačen time, da je za uporabu u liječenju raka mjehura, mozga, dojki i maternice, kronične limfoidne leukemije, raka debelog crijeva, raka jednjaka i jetre, leukemije limfoblasta, ne-Hodgkinovog limfoma, melanoma, maligne hemopatije, mijcloma, raka jajnika, raka pluća nc-malih stanica, raka prostate i raka pluća malih stanica.
26. Uporaba farmaceutskog pripravka u skladu s patentnim zahtjevom 22, naznačena time, da je za proizvodnju lijeka za uporabu kao apoptotičkog sredstva.
27. Uporaba farmaceutskog pripravka u skladu s patentnim zahtjevom 22, naznačena time, da je za proizvodnju lijeka za liječenje karcinoma, bolesti imunog sustava i auto-imunih bolesti.
28. Uporaba farmaceutskog pripravka u skladu s patentnim zahtjevom 22, naznačena time, da je za proizvodnju lijeka namijenjenog za liječenje raka mjehura, mozga, dojki i maternice, kronične limfoidne leukemije, raka debelog crijeva, raka jednjaka i jetre, leukemije limfoblasta, ne-Hodgkinovog limfoma, melanoma, maligne hemopatije, mijeloma, raka jajnika, raka pluća nc-malih stanica, raka prostate i raka pluća malih stanica.
29. Spoj formule (I) u skladu s jednim od patentnih zahtjeva 1 do 19, ili njegova adicijska sol s farmaceutski prihvatljivom kiselinom ili lužinom, naznačen time, da se koristi u liječenju raka mjehura, mozga, dojki i maternice, kronične limfoidne leukemije, raka debelog crijeva, raka jednjaka i jetre, leukemije limfoblasta, ne-Hodgkinovog limfoma, melanoma, maligne hemopatije, mijeloma, raka jajnika, raka pluća ne-malih stanica, raka prostate i raka pluća malih stanica.
30. Uporaba spoja formule (I) u skladu s jednim od patentnih zahtjeva 1 do 19, ili njegova adicijska sol s farmaceutski prihvatljivom kiselinom ili lužinom, naznačen time, da je za proizvodnju lijeka namijenjenog za liječenje raka mjehura, mozga, dojki i maternice, kronične limfoidne leukemije, raka debelog crijeva, raka jednjaka i jetre, leukemije limfoblasta, ne-Hodgkinovog limfoma, melanoma, maligne hemopatije, mijeloma, raka jajnika, raka pluća ne-malih stanica, raka prostate i raka pluća malih stanica.
31. Kombinacija spoja formule (I) u skladu s bilo kojim od patentnih zahtjeva 1 do 19, naznačen time, da se kombinira s protutumorskim sredstvom koje je odabrano od genotoksičnih sredstava, mitotičkih otrova, antimetabolita, inhibitora proteazoma, inhibitora kinaze i protutijela.
32. Farmaceutski pripravak koji sadrži kombinaciju u skladu s patentnim zahtjevom 31, naznačen time, da se kombinira s jednim ili više farmaceutski prihvatljivih ekscipijensa.
33. Kombinacija u skladu s patentnim zahtjevom 31, naznačeno time, da je za uporabu u liječenju karcinoma.
34. Uporaba kombinacije u skladu s patentnim zahtjevom 31, naznačena time, da je za proizvodnju lijeka za uporabu u liječenju karcinoma.
35. Spoj formule (I) u skladu s bilo kojim od patentnih zahtjeva 1 do 19, naznačen time, da je za uporabu u kombinaciji s radioterapijom za liječenje karcinoma.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1357258A FR3008975A1 (fr) | 2013-07-23 | 2013-07-23 | Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
EP14178016.3A EP2829539B1 (fr) | 2013-07-23 | 2014-07-22 | Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20170349T1 true HRP20170349T1 (hr) | 2017-04-21 |
Family
ID=50023639
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20170349TT HRP20170349T1 (hr) | 2013-07-23 | 2017-03-02 | Novi derivati pirola, postupak njihove priprave i farmaceutski pripravci koji ih sadrže |
Country Status (48)
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3008975A1 (fr) * | 2013-07-23 | 2015-01-30 | Servier Lab | Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
AU2017300738A1 (en) | 2016-07-22 | 2019-02-07 | Les Laboratoires Servier | Combination of a BCL-2 inhibitor and a MCL-1 inhibitor, uses and pharmaceutical compositions thereof |
UA125138C2 (uk) * | 2016-07-22 | 2022-01-19 | Ле Лаборатуар Сервьє | Комбінація інгібітора bcl-2 та інгібітора mcl-1, їхнє застосування і фармацевтичні композиції |
WO2018158225A1 (en) | 2017-02-28 | 2018-09-07 | Les Laboratoires Servier | Combination of a bcl-2 inhibitor and a mdm2 inhibitor, uses and pharmaceutical compositions thereof |
FR3072679B1 (fr) * | 2017-10-25 | 2020-10-30 | Servier Lab | Nouveaux derives macrocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
EP3873894B1 (en) * | 2018-10-31 | 2023-03-22 | Les Laboratoires Servier | Novel salt of a bcl-2 inhibitor, related crystalline form, method for preparing the same and pharmaceutical compositions containing the same |
UY38431A (es) * | 2018-10-31 | 2020-05-29 | Servier Lab | Formulación basada en ciclodextrina de un inhibidor de bcl-2 |
WO2020139044A1 (ko) * | 2018-12-27 | 2020-07-02 | 홀로스메딕 주식회사 | 신규한 화합물 및 이를 포함하는 항암 활성 증진용 약학 조성물 |
HRP20231498T1 (hr) * | 2019-05-14 | 2024-03-01 | Les Laboratoires Servier | Bcl-2 inhibitori za upotrebu u liječenju raka posredovanog bcl-2 koji nosi gly101val mutaciju |
WO2020236825A2 (en) | 2019-05-20 | 2020-11-26 | Novartis Ag | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
JP2023537290A (ja) | 2020-07-31 | 2023-08-31 | レ ラボラトワール セルヴィエ | 癌を処置するためのBcl-2阻害薬と低メチル化剤との組合せ、その使用及び医薬組成物 |
WO2022090443A1 (en) | 2020-10-30 | 2022-05-05 | Les Laboratoires Servier | Administration and dose regimen for a combination of a bcl-2 inhibitor and a mcl1 inhibitor |
US20240042051A1 (en) | 2020-11-24 | 2024-02-08 | Francesca Rocchetti | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
IL304891A (en) | 2021-02-02 | 2023-10-01 | Servier Lab | Selective Protech BCL-XL compounds and methods of use |
CN113129644B (zh) * | 2021-03-05 | 2022-03-08 | 中国人民解放军国防科技大学 | 基于球面扫描线的船舶三维特征航线提取方法 |
CN116997544A (zh) | 2021-03-24 | 2023-11-03 | 法国施维雅药厂 | 用于合成5-{5-氯-2-[(3s)-3-[(吗啉-4-基)甲基]-3,4-二氢异喹啉-2(1h)-羰基]苯基}-1,2-二甲基-1h-吡咯-3-甲酸衍生物的新方法及其在生产药物化合物中的应用 |
WO2022228215A1 (zh) * | 2021-04-26 | 2022-11-03 | 广东东阳光药业有限公司 | 吡咯酰胺化合物的制备方法 |
WO2023129553A1 (en) * | 2021-12-29 | 2023-07-06 | Eil Therapeutics, Inc. | Bcl-2 inhibitors |
CN114736156B (zh) * | 2022-05-18 | 2024-03-19 | 中捷四方生物科技股份有限公司 | 一种白叶藤碱简化衍生物的制备方法及用途 |
WO2023225320A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
WO2023225359A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Antibody-drug conjugates of antineoplastic compounds and methods of use thereof |
WO2023225336A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0807632B1 (en) | 1995-12-01 | 2002-04-17 | Suntory Limited | Pyrroloazepine derivatives |
US7122544B2 (en) | 2000-12-06 | 2006-10-17 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto |
CA2577752A1 (en) | 2004-08-20 | 2006-03-02 | The Regents Of The University Of Michigan | Small molecule inhibitors of anti-apoptotic bcl-2 family members and the uses thereof |
WO2006052568A2 (en) | 2004-11-10 | 2006-05-18 | Eli Lilly And Company | Tgf-beta inhibitors |
JP2008530174A (ja) * | 2005-02-15 | 2008-08-07 | ノボ ノルディスク アクティーゼルスカブ | 3,4−ジヒドロ−1h−イソキノリン−2−カルボン酸5−アミノピリジン−2−イルエステル |
JP2008531671A (ja) * | 2005-03-04 | 2008-08-14 | アストラゼネカ アクチボラグ | 化合物 |
SE531110C2 (sv) | 2006-07-14 | 2008-12-23 | Vaelinge Innovation Ab | Låssystem omfattande ett kombinationslås för paneler |
BRPI0714346A2 (pt) | 2006-07-14 | 2013-03-19 | Genelabs Tech Inc | agentes antivirais |
US7706888B2 (en) | 2006-07-14 | 2010-04-27 | Med-El Elektromedizinische Geraete Gmbh | Bi-planar electrode with shunting gates |
CN102007101A (zh) | 2007-11-30 | 2011-04-06 | 生物区科学管理控股有限公司 | 作为抗菌剂的四氢-异喹啉ppat抑制剂 |
EP2373163B1 (en) | 2008-12-19 | 2015-06-10 | Genentech, Inc. | Heterocyclic compounds and methods of use |
US8557612B2 (en) | 2009-06-26 | 2013-10-15 | California Institute Of Technology | Method for fabricating micro and nanostructures in a material |
EP2714681B1 (en) * | 2011-05-25 | 2015-06-24 | Bristol-Myers Squibb Company | Substituted sulfonamides useful as antiapoptotic bcl inhibitors |
EP2794592A1 (en) | 2011-12-23 | 2014-10-29 | Novartis AG | Compounds for inhibiting the interaction of bcl2 with binding partners |
JP2015503517A (ja) * | 2011-12-23 | 2015-02-02 | ノバルティス アーゲー | Bcl2と結合相手の相互作用を阻害するための化合物 |
FR2986002B1 (fr) * | 2012-01-24 | 2014-02-21 | Servier Lab | Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
FR3008975A1 (fr) * | 2013-07-23 | 2015-01-30 | Servier Lab | Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
-
2013
- 2013-07-23 FR FR1357258A patent/FR3008975A1/fr active Pending
-
2014
- 2014-06-24 IL IL233343A patent/IL233343A/en active IP Right Grant
- 2014-06-24 JO JOP/2014/0198A patent/JO3275B1/ar active
- 2014-06-25 TN TNP2014000278A patent/TN2014000278A1/fr unknown
- 2014-06-25 CR CR20140307A patent/CR20140307A/es unknown
- 2014-06-25 PH PH12014000179A patent/PH12014000179A1/en unknown
- 2014-06-26 PE PE2014001034A patent/PE20150399A1/es active IP Right Grant
- 2014-06-26 PE PE2019000414A patent/PE20190653A1/es unknown
- 2014-06-27 AU AU2014203521A patent/AU2014203521B2/en active Active
- 2014-06-30 DO DO2014000154A patent/DOP2014000154A/es unknown
- 2014-07-01 UY UY35639A patent/UY35639A/es active IP Right Grant
- 2014-07-01 SG SG10201403750UA patent/SG10201403750UA/en unknown
- 2014-07-02 MY MYPI2014701840A patent/MY173259A/en unknown
- 2014-07-04 GT GT201400144A patent/GT201400144A/es unknown
- 2014-07-07 CU CUP2014000081A patent/CU24315B1/xx unknown
- 2014-07-09 TW TW103123702A patent/TWI549948B/zh active
- 2014-07-10 CA CA2856505A patent/CA2856505C/fr active Active
- 2014-07-11 MA MA37206A patent/MA37206B1/fr unknown
- 2014-07-14 CL CL2014001853A patent/CL2014001853A1/es unknown
- 2014-07-15 MD MDA20140072A patent/MD4575C1/ro active IP Right Grant
- 2014-07-17 UA UAA201408110A patent/UA115773C2/uk unknown
- 2014-07-17 SV SV2014004770A patent/SV2014004770A/es unknown
- 2014-07-18 ZA ZA2014/05323A patent/ZA201405323B/en unknown
- 2014-07-21 AR ARP140102677A patent/AR096979A1/es active IP Right Grant
- 2014-07-21 US US14/336,311 patent/US9108983B2/en active Active
- 2014-07-21 GE GEAP201413527A patent/GEP201706686B/en unknown
- 2014-07-22 RS RS20170254A patent/RS55838B1/sr unknown
- 2014-07-22 EA EA201400753A patent/EA026906B1/ru unknown
- 2014-07-22 MX MX2014008867A patent/MX348370B/es active IP Right Grant
- 2014-07-22 ES ES14178016.3T patent/ES2620515T3/es active Active
- 2014-07-22 PL PL14178016T patent/PL2829539T3/pl unknown
- 2014-07-22 PT PT141780163T patent/PT2829539T/pt unknown
- 2014-07-22 LT LTEP14178016.3T patent/LT2829539T/lt unknown
- 2014-07-22 DK DK14178016.3T patent/DK2829539T3/en active
- 2014-07-22 NI NI201400079A patent/NI201400079A/es unknown
- 2014-07-22 BR BR102014017950A patent/BR102014017950B1/pt active IP Right Grant
- 2014-07-22 WO PCT/FR2014/051888 patent/WO2015011400A1/fr active Application Filing
- 2014-07-22 RU RU2014130125A patent/RU2607788C2/ru active
- 2014-07-22 EP EP14178016.3A patent/EP2829539B1/fr active Active
- 2014-07-22 ME MEP-2017-63A patent/ME02635B/me unknown
- 2014-07-22 SA SA114350670A patent/SA114350670B1/ar unknown
- 2014-07-22 JP JP2014148956A patent/JP5923560B2/ja active Active
- 2014-07-22 SI SI201430163A patent/SI2829539T1/sl unknown
- 2014-07-22 HU HUE14178016A patent/HUE033361T2/hu unknown
- 2014-07-23 CN CN201611227370.4A patent/CN106674196A/zh not_active Withdrawn
- 2014-07-23 CN CN201611227395.4A patent/CN106674201A/zh not_active Withdrawn
- 2014-07-23 KR KR1020140093481A patent/KR101712111B1/ko active IP Right Grant
- 2014-07-23 CN CN201410351234.0A patent/CN104341395B/zh active Active
-
2015
- 2015-03-02 HK HK15102102.4A patent/HK1201529A1/xx unknown
- 2015-05-04 HK HK15104232.3A patent/HK1203506A1/xx unknown
- 2015-07-13 US US14/797,532 patent/US9598427B2/en active Active
-
2016
- 2016-12-23 KR KR1020160178093A patent/KR20170001695A/ko not_active Application Discontinuation
-
2017
- 2017-01-30 US US15/419,228 patent/US10265323B2/en active Active
- 2017-03-02 HR HRP20170349TT patent/HRP20170349T1/hr unknown
- 2017-03-20 CY CY20171100352T patent/CY1118756T1/el unknown
-
2019
- 2019-02-08 US US16/271,171 patent/US10688101B2/en active Active
-
2020
- 2020-05-04 US US16/865,855 patent/US11058689B2/en active Active
-
2021
- 2021-06-08 US US17/341,751 patent/US20210290631A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20170349T1 (hr) | Novi derivati pirola, postupak njihove priprave i farmaceutski pripravci koji ih sadrže | |
US11485745B2 (en) | Amido spirocyclic amide and sulfonamide derivatives | |
HRP20170153T1 (hr) | Novi derivati indolizina, postupak njihove priprave i farmaceutski pripravci koji ih sadrže za liječenje karcinoma | |
HRP20171752T1 (hr) | Novi derivati indolizina, postupak za njihovu pripravu i farmaceutski pripravci koji ih sadrže | |
AU2018364938B2 (en) | Macrocyclic compounds as TRK kinase inhibitors and uses thereof | |
ES2840454T3 (es) | Intermedio sintético útil en la preparación de inhibidores de c-Met triazolopiridínicos | |
HRP20161202T1 (hr) | Novi derivati fosfata, postupak njihove priprave i farmaceutski pripravci koji ih sadrže | |
HRP20200107T1 (hr) | Novi derivati hidroksiestera, postupak za njihovu pripravu i farmaceutski pripravci koji ih sadrže | |
JP2023078421A (ja) | タンパク質チロシンホスファターゼ阻害剤 | |
CA3085259A1 (en) | Substituted bicyclic heterocyclic compounds as prmt5 inhibitors | |
ES2747909T3 (es) | Inhibidores duales de quinasas ITK y JAK3 de 3,5-(no)sustituida-1H-pirrolo[2,3-b]piridina, 1H-pirazolo[3,4-b]piridina y 5H-pirrolo[2,3-b]pirazina | |
AU2011311867A1 (en) | Furo(3,2-d)pyrimidine compounds | |
JP2015508785A (ja) | ピリジニル及びピリミジニルスルホキシド及びスルホン誘導体 | |
JP2021506979A (ja) | ホスファチジルイノシトールリン酸キナーゼ阻害剤としてのアリール−ビピリジンアミン誘導体 | |
BR112021005896A2 (pt) | moduladores da monoacilglicerol lipase | |
TW202321242A (zh) | 雜環化合物及使用方法 | |
HRP20201754T1 (hr) | Supstituirani pirido[3,4-b]indoli za liječenje poremećaja hrskavice | |
CA3198809A1 (en) | Heterocyclic spiro compounds and methods of use | |
EP4288435A1 (en) | Tricyclic-amido-bicyclic prmt5 inhibitors | |
KR20140103972A (ko) | 세린/트레오닌 키나아제 억제제로서의 2,4-다이아민-피리미딘 유도체 | |
KR20200138306A (ko) | 헤테로시클릭 화합물 | |
JPWO2020032105A5 (hr) | ||
AU2022323373A1 (en) | Pyrimidine or pyridine derivative, preparation method therefor, and application thereof in pharmacy | |
EP4347594A1 (en) | 2, 8-diazaspiro [4.5] decane compounds | |
JP2023542789A (ja) | ピラゾール化合物並びにその調製方法及び使用 |